Linear energy transfer

Radiation-Tolerant DC-DC 50-Watt Power Converters Provide High-Reliability Solution for New Space Applications

Retrieved on: 
Mardi, mai 7, 2024
QML, Radiation, Microchip Technology, LEO, Internet of things, Integrated circuit, MCHP, DC-DC, Family, Field-programmable gate array, EMI, TID, RT, Linear energy transfer, COTS

There is an increased demand for standard space grade solutions that are reliable, cost effective and configurable.

Key Points: 
  • There is an increased demand for standard space grade solutions that are reliable, cost effective and configurable.
  • The off-the-shelf LE50-28 family of power converters are designed to meet MIL-STD-461.
  • This series provides flexibility to parallel up to four power converters to reach 200-Watts.
  • Designed to serve 28V bus systems, the LE50-28 isolated DC-DC power converters can be integrated with Microchip’s PolarFire® FPGAs, microcontrollers and LX7720-RT motor control sensor for a complete electrical system solution.

RaySearch to present the latest advances in RayStation, RayCare and RayIntelligence at ESTRO 2024

Retrieved on: 
Jeudi, mai 2, 2024
Congress, News, LET, Radiation, GE HealthCare, Accuray, Automation, SRS, Linear energy transfer, Neoplasm, Health, Deep learning, Medical imaging

STOCKHOLM, May 2, 2024 /PRNewswire/ -- RaySearch will be showcasing its latest software innovations at ESTRO in Glasgow, May 3-6.

Key Points: 
  • STOCKHOLM, May 2, 2024 /PRNewswire/ -- RaySearch will be showcasing its latest software innovations at ESTRO in Glasgow, May 3-6.
  • Attendees will be able to book demonstrations of the treatment planning system RayStation®*, the oncology information system RayCare®*, and the cloud-based oncology analytics system RayIntelligence® during the congress.
  • Additionally, RaySearch will present joint solutions with industry partners IBA, Vision RT, Accuray, GE Healthcare, and Leo Cancer Care.
  • This year I am particularly happy to present our latest developments within online adaptive and several significant partner collaborations.

RaySearch to present latest innovations in RayStation, RayCare and RayIntelligence at ISOP and NPC (NAPT)

Retrieved on: 
Jeudi, avril 4, 2024
Proton, NAPT, Conference, Proton therapy, Research, NPC, RBE, RaySearch Laboratories, Linear energy transfer, Future, National Association, LET, Medical imaging

STOCKHOLM, April 4, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) will present the latest software innovations at IBA's International Symposium on Proton Therapy (ISOP) in Boston, Massachusetts, April 5, and at the National Proton Conference (NPC) run by the National Association on Proton Therapy (NAPT) in Boston, April 6-9.

Key Points: 
  • STOCKHOLM, April 4, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) will present the latest software innovations at IBA's International Symposium on Proton Therapy (ISOP) in Boston, Massachusetts, April 5, and at the National Proton Conference (NPC) run by the National Association on Proton Therapy (NAPT) in Boston, April 6-9.
  • Visit us at RaySearch's table at ISOP and booth at NPC.
  • The focus during both ISOP and NPC will be on support for proton arcs and robust optimization based on linear energy transfer (LET) and adaptive therapy.
  • Marc Mlyn, President of RaySearch Americas, and David McPhail, VP of Sales for RaySearch Americas, will be present at the meetings and look forward to meeting existing and future clinical partners.

Actinium Pharmaceuticals Launches Actinium-225 Focused Strategic Initiative to Leverage Proprietary Cyclotron Based Manufacturing Technology to Address Growing Market Demand

Retrieved on: 
Lundi, mars 11, 2024
Actinium, Synthase, NCI, Recycling, Actinium-225, International, CRADA, DNA, Research, Thorium, Linear energy transfer, Investment, Cyclotron, DOE, Medicine

Actinium's intellectual property portfolio relating to its cyclotron-based production method includes 5 issued U.S. patents and 49 issued international patents as well as significant technical know-how.

Key Points: 
  • Actinium's intellectual property portfolio relating to its cyclotron-based production method includes 5 issued U.S. patents and 49 issued international patents as well as significant technical know-how.
  • The DOE has stated that it is exploring the generation of new thorium cows and production via a cyclotron.
  • Based on our experience to date, we expect to be able to produce material with high radiochemical purity and at yields not possible with thorium-cow based methods.
  • This has the potential to further establish Actinium as a leader in alpha-particle therapies and remain at the forefront of innovation while addressing a significant and rapidly growing addressable patient population."

Latest innovations in RayStation, RayCare and RayIntelligence to be presented at ASTRO 2023

Retrieved on: 
Vendredi, septembre 29, 2023
ASTRO, RaySearch Laboratories, DICOM, Congress, Photon, LET, Linear energy transfer, Medical imaging

STOCKHOLM, Sept. 29, 2023 /PRNewswire/ -- RaySearch will be showcasing the latest software innovations at ASTRO in San Diego, California, October 1-4.

Key Points: 
  • STOCKHOLM, Sept. 29, 2023 /PRNewswire/ -- RaySearch will be showcasing the latest software innovations at ASTRO in San Diego, California, October 1-4.
  • Participants can book demonstrations of RayStation®* treatment planning system, RayCare®* oncology information system, and cloud-based oncology analytics system RayIntelligence®, in RaySearchs's booth 3245 during the event.
  • RaySearch's latest product, the cloud-based oncology analytics system RayIntelligence will also be demonstrated during the congress.
  • We are also eager to showcase our latest product innovations to attendees joining us in our booth."

Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer

Retrieved on: 
Jeudi, août 24, 2023
KLK, Radiation, RAD, Radionuclide, PSMA, Cancer, ASX, Cell, Brain, Invention, KLK3, Linear energy transfer, Patient, Mab, Kidney, Safety, Prostate cancer, Medical imaging, Alpha, Auger

KLK3 is highly expressed in prostate cancer cells but has limited expression in healthy tissue.

Key Points: 
  • KLK3 is highly expressed in prostate cancer cells but has limited expression in healthy tissue.
  • Radiopharm will initiate a Phase I dose escalating trial evaluating the safety and efficacy of RAD 402 in patients with advanced prostate cancer, during the second half of 2024.
  • “We are excited about bringing this highly differentiated technology (Tb161-RAD402) to patients with advanced prostate cancer.
  • This novel radiopharmaceutical has the potential to become the first KLK-based theranostic option for individuals with advanced prostate cancer.

RaySearch to present the latest advances in RayStation, RayCare and RayIntelligence at AAPM 2023

Retrieved on: 
Lundi, juillet 24, 2023
Photon, LET, Health, AAPM, RaySearch Laboratories, DICOM, Research, Lausanne University Hospital, Doctor of Philosophy, Véronique, University of Lausanne, Congress, Linear energy transfer, Medical imaging

STOCKHOLM, July 23, 2023 /PRNewswire/ -- The latest version of RayStation includes among others support for automatic field-in-field planning for photons, a method that generates homogeneous and conformal dose distributions by combining a few subfields, as well as point-based optimization of brachy plans, and faster loading of data. Attendees will also be able to experience the next steps in workflow improvements for dosetracking and adaptive replanning. Within particle therapy planning, support for proton arcs and robust optimization based on linear energy transfer (LET) will be showed.

Key Points: 
  • RaySearch will be showcasing the latest software innovations at AAPM in Houston, Texas, July 23-27.
  • Attendees will be able to book demonstrations of RayStation®* treatment planning system, RayCare®* oncology information system, and the cloud-based oncology analytics system RayIntelligence® during the congress.
  • Attendees will also be able to experience the next steps in workflow improvements for dosetracking and adaptive replanning.
  • Within particle therapy planning, support for proton arcs and robust optimization based on linear energy transfer (LET) will be showed.

RaySearch releases RayStation 2023B

Retrieved on: 
Mercredi, juillet 12, 2023
RaySearch Laboratories, Neoplasm, Radiation, Probability, GSI Helmholtz Centre for Heavy Ion Research, Health, Research, Photon, LET, Workflow, Carbon, Noetics, Linear energy transfer, Pharmaceutical industry, Medical imaging

STOCKHOLM, July 12, 2023 /PRNewswire/ -- Radiation therapy becomes more and more tailored to each patient with highly conformal dose delivery to the tumor and reduced exposure of normal tissue. More precise treatment plans require a higher level of follow-up throughout the course of treatment to ensure that the planned dose stays on track, as well as possibilities to adapt the plan if deviations are found. RaySearch has conducted research within adaptive replanning for two decades and when entering the field of treatment planning with RayStation, the system was designed from start with dose tracking and adaptive replanning in mind. RayStation 2023B takes the next steps and improves the workflows for dose tracking and replanning further.

Key Points: 
  • RaySearch Laboratories AB (publ) announces the launch of RayStation®* 2023B, the latest version of the company's comprehensive oncology treatment planning system.
  • RayStation 2023B takes the next steps and improves the workflows for dose tracking and replanning further.
  • With the combination of RayStation 2023B and RayCare 2023B all necessary treatment plan information is available in RayCare when selecting which plan to deliver at a certain fraction.
  • Johan Löf, founder and CEO, RaySearch, says: "With RayStation 2023B we show our strong dedication in providing world-class solutions for treatment planning.

Radiopharm Theranostics Enters Into Supply Agreement with TerThera for Terbium-161 Isotope

Retrieved on: 
Lundi, avril 17, 2023
Brain, Radiation, RAD, Radionuclide, Calendar, Clinical trial, Cancer, ASX, Invention, Patient, Linear energy transfer, Rare-earth element, Medical imaging, Auger

SYDNEY, Australia, April 17, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce an agreement with TerThera to supply the Company with Terbium-161 (Tb-161).

Key Points: 
  • SYDNEY, Australia, April 17, 2023 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce an agreement with TerThera to supply the Company with Terbium-161 (Tb-161).
  • Radiopharm will initiate a Phase I dose escalating trial of RAD 602 for treatment of patients with brain cancers during the fourth quarter of calendar 2023.
  • The effective date of the supply agreement is 17 April 2023 and there are no material preconditions.
  • Radiopharm will own all data generated and all inventions and discoveries made or conceived from its clinical trials.

Oncoinvent Initiates Radspherin® Phase 2A Trial

Retrieved on: 
Jeudi, août 25, 2022
Research, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, General Health, Science, Oncology, Radium, Transfer, Sweden, Cancer, Safety, Radionuclide, LET, Uppsala University Hospital, Radiation, Linear energy transfer, Alpha, Oslo University Hospital, Radiumhospitalet, Clinical trial, HIPEC, Ovarian cancer, Colorectal cancer, Patient, Pharmaceutical industry, Medical imaging

Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, today announced that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin.

Key Points: 
  • Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a variety of cancers, today announced that the first colorectal cancer patient in the RAD-18-002 phase 2A clinical trial has been treated with its drug candidate, Radspherin.
  • The start of the RAD-18-002 phase 2A study marks an entry into the next stage of development for both our product candidate Radspherin as well as for Oncoinvent, said Jan A. Alfheim, Chief Executive Officer of Oncoinvent.
  • The phase 2A open-label expansion cohort of the RAD-18-002 clinical trial is designed to assess the safety, tolerability, and anti-tumor activity of Radspherin, an -emitting radionuclide therapy, administered into the intraperitoneal cavity in subjects with peritoneal carcinomatosis from colorectal carcinoma following complete cytoreductive surgery and HIPEC.
  • Oncoinvent AS is a clinical stage company developing innovative radiopharmaceutical technology that delivers precise, alpha-emitting particles across various cancers.